Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers
This study elucidated the clinical, humoral immune response and genomic analysis of vaccine breakthrough (VBT) infections after ChAdOx1 nCoV-19/Covishield vaccine in healthcare workers (HCWs). Amongst 1858 HCWs, 1639 had received either two doses (1346) or a single dose (293) of ChAdOx1 nCoV-19 vacc...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/1/54 |
| _version_ | 1797489899306221568 |
|---|---|
| author | Pratibha Kale Ekta Gupta Chhagan Bihari Niharika Patel Sheetalnath Rooge Amit Pandey Meenu Bajpai Vikas Khillan Partha Chattopadhyay Priti Devi Ranjeet Maurya Neha Jha Priyanka Mehta Manish Kumar Pooja Sharma Sheeba Saifi Aparna Swaminathan Sarfaraz Alam Bharathram Uppili Mohammed Faruq Anurag Agrawal Rajesh Pandey Shiv Kumar Sarin |
| author_facet | Pratibha Kale Ekta Gupta Chhagan Bihari Niharika Patel Sheetalnath Rooge Amit Pandey Meenu Bajpai Vikas Khillan Partha Chattopadhyay Priti Devi Ranjeet Maurya Neha Jha Priyanka Mehta Manish Kumar Pooja Sharma Sheeba Saifi Aparna Swaminathan Sarfaraz Alam Bharathram Uppili Mohammed Faruq Anurag Agrawal Rajesh Pandey Shiv Kumar Sarin |
| author_sort | Pratibha Kale |
| collection | DOAJ |
| description | This study elucidated the clinical, humoral immune response and genomic analysis of vaccine breakthrough (VBT) infections after ChAdOx1 nCoV-19/Covishield vaccine in healthcare workers (HCWs). Amongst 1858 HCWs, 1639 had received either two doses (1346) or a single dose (293) of ChAdOx1 nCoV-19 vaccine. SARS-CoV-2 IgG antibodies and neutralizing antibodies were measured in the vaccinated group and the development of SARS-CoV-2 infection was monitored.Forty-six RT-PCR positive samples from the 203 positive samples were subjected to whole genome sequencing (WGS). Of the 203 (10.92%) infected HCWs, 21.46% (47/219) were non-vaccinated, which was significantly more than 9.52% (156/1639) who were vaccinated and infection was higher in doctors and nurses. Unvaccinated HCWs had 1.57 times higher risk compared to partially vaccinated HCWs and 2.49 times higher risk than those who were fully vaccinated.The partially vaccinated were at higher risk than the fully vaccinated (RR 1.58). Antibody non-response was seen in 3.44% (4/116), low antibody levels in 15.51% (18/116) and medium levels were found in 81.03% (94/116). Fully vaccinated HCWs had a higher antibody response at day 42 than those who were partially vaccinated (8.96 + 4.00 vs. 7.17 + 3.82). Whole genome sequencing of 46 samples revealed that the Delta variant (B.1.617.2) was predominant (69.5%). HCWs who had received two doses of vaccine showed better protection from mild, moderate, or severe infection, with a higher humoral immune response than those who had received a single dose. The genomic analysis revealed the predominance of the Delta variant (B.1.617.2) in the VBT infections. |
| first_indexed | 2024-03-10T00:24:12Z |
| format | Article |
| id | doaj.art-de863b55bd1d41d28307bda1baa7ba47 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T00:24:12Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-de863b55bd1d41d28307bda1baa7ba472023-11-23T15:38:36ZengMDPI AGVaccines2076-393X2021-12-011015410.3390/vaccines10010054Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare WorkersPratibha Kale0Ekta Gupta1Chhagan Bihari2Niharika Patel3Sheetalnath Rooge4Amit Pandey5Meenu Bajpai6Vikas Khillan7Partha Chattopadhyay8Priti Devi9Ranjeet Maurya10Neha Jha11Priyanka Mehta12Manish Kumar13Pooja Sharma14Sheeba Saifi15Aparna Swaminathan16Sarfaraz Alam17Bharathram Uppili18Mohammed Faruq19Anurag Agrawal20Rajesh Pandey21Shiv Kumar Sarin22Department of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Hepatopathology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaDepartment of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaCouncil for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, IndiaDepartment of Hepatology, Institute of Liver and Biliary Sciences, New Delhi 110070, IndiaThis study elucidated the clinical, humoral immune response and genomic analysis of vaccine breakthrough (VBT) infections after ChAdOx1 nCoV-19/Covishield vaccine in healthcare workers (HCWs). Amongst 1858 HCWs, 1639 had received either two doses (1346) or a single dose (293) of ChAdOx1 nCoV-19 vaccine. SARS-CoV-2 IgG antibodies and neutralizing antibodies were measured in the vaccinated group and the development of SARS-CoV-2 infection was monitored.Forty-six RT-PCR positive samples from the 203 positive samples were subjected to whole genome sequencing (WGS). Of the 203 (10.92%) infected HCWs, 21.46% (47/219) were non-vaccinated, which was significantly more than 9.52% (156/1639) who were vaccinated and infection was higher in doctors and nurses. Unvaccinated HCWs had 1.57 times higher risk compared to partially vaccinated HCWs and 2.49 times higher risk than those who were fully vaccinated.The partially vaccinated were at higher risk than the fully vaccinated (RR 1.58). Antibody non-response was seen in 3.44% (4/116), low antibody levels in 15.51% (18/116) and medium levels were found in 81.03% (94/116). Fully vaccinated HCWs had a higher antibody response at day 42 than those who were partially vaccinated (8.96 + 4.00 vs. 7.17 + 3.82). Whole genome sequencing of 46 samples revealed that the Delta variant (B.1.617.2) was predominant (69.5%). HCWs who had received two doses of vaccine showed better protection from mild, moderate, or severe infection, with a higher humoral immune response than those who had received a single dose. The genomic analysis revealed the predominance of the Delta variant (B.1.617.2) in the VBT infections.https://www.mdpi.com/2076-393X/10/1/54vaccine breakthrough infectionsCOVID-19healthcare workersdelta variantimmune response |
| spellingShingle | Pratibha Kale Ekta Gupta Chhagan Bihari Niharika Patel Sheetalnath Rooge Amit Pandey Meenu Bajpai Vikas Khillan Partha Chattopadhyay Priti Devi Ranjeet Maurya Neha Jha Priyanka Mehta Manish Kumar Pooja Sharma Sheeba Saifi Aparna Swaminathan Sarfaraz Alam Bharathram Uppili Mohammed Faruq Anurag Agrawal Rajesh Pandey Shiv Kumar Sarin Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers Vaccines vaccine breakthrough infections COVID-19 healthcare workers delta variant immune response |
| title | Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers |
| title_full | Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers |
| title_fullStr | Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers |
| title_full_unstemmed | Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers |
| title_short | Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers |
| title_sort | vaccine breakthrough infections by sars cov 2 variants after chadox1 ncov 19 vaccination in healthcare workers |
| topic | vaccine breakthrough infections COVID-19 healthcare workers delta variant immune response |
| url | https://www.mdpi.com/2076-393X/10/1/54 |
| work_keys_str_mv | AT pratibhakale vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT ektagupta vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT chhaganbihari vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT niharikapatel vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT sheetalnathrooge vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT amitpandey vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT meenubajpai vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT vikaskhillan vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT parthachattopadhyay vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT pritidevi vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT ranjeetmaurya vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT nehajha vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT priyankamehta vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT manishkumar vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT poojasharma vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT sheebasaifi vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT aparnaswaminathan vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT sarfarazalam vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT bharathramuppili vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT mohammedfaruq vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT anuragagrawal vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT rajeshpandey vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers AT shivkumarsarin vaccinebreakthroughinfectionsbysarscov2variantsafterchadox1ncov19vaccinationinhealthcareworkers |